Krystal Biotech Inc (KRYS)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those...

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803...

Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements